2022 World Conference on Lung Cancer (ePosters)-EP08.02-028. Germline HRR Mutations in Metastatic NSCLC and Impact on Progression-Free Survival: A Single-Center Retrospective Study

EP08.02-028. Germline HRR Mutations in Metastatic NSCLC and Impact on Progression-Free Survival: A Single-Center Retrospective Study

Back to course

Pdf Summary

A retrospective study was conducted to investigate the impact of germline mutations in genes involved in homologous recombination repair (HRR) in patients with advanced non-small cell lung cancer (NSCLC). The study found that patients with incidentally found germline HRR mutations had shorter progression-free survival (PFS) on targeted therapy compared to patients without these mutations, especially those with de novo stage IV disease. <br /><br />The study included 9 patients with germline HRR mutations and known dates of systemic therapy. Among these patients, 4 had de novo stage IV NSCLC and 3 had initial earlier-stage disease with subsequent recurrence. All 7 patients with oncogene-driven NSCLC received targeted therapy at the time of metastatic diagnosis. The median PFS on targeted therapies was 11.4 months for the entire cohort. For patients with de novo stage IV disease, the median PFS was 9.2 months, while for those with early-stage disease that progressed, the median PFS was 44.2 months. Similarly, among patients with EGFR mutated disease, the median PFS was 27.4 months, with 9.3 months for de novo stage IV disease and 49.8 months for early-stage disease that progressed. <br /><br />The findings of this study suggest that testing for HRR genes in lung cancer patients is necessary, and further research is needed to understand the underlying reasons behind the shorter PFS observed in patients with germline HRR mutations. The study also raises the question of whether PARP inhibition could be an effective treatment strategy for lung cancer patients with oncogene-driven NSCLC and germline HRR mutations. Overall, this study highlights the importance of identifying and studying germline mutations in HRR genes in patients with advanced NSCLC.

Asset Subtitle

Chetan Vakkalagadda

Meta Tag

Speaker Chetan Vakkalagadda

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

retrospective study

germline mutations

homologous recombination repair

non-small cell lung cancer

progression-free survival

targeted therapy

de novo stage IV disease

oncogene-driven NSCLC

EGFR mutated disease

PARP inhibition